SARS-CoV-2 adaptive immunity in nursing home residents up to eight months after two doses of the Comirnaty® COVID-19 vaccine.
Comirnaty® COVID-19 vaccine
SARS-CoV-2
SARS-CoV-2-S T cells
SARS-CoV-2-S antibodies
nursing home residents
Journal
The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
14
02
2022
accepted:
27
02
2022
pubmed:
5
3
2022
medline:
26
5
2022
entrez:
4
3
2022
Statut:
ppublish
Résumé
Burgos JS (General Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain); Meneu de Guillerna R (Vice-President Foundation Research Institute in Public Services, Valencia, Spain); Vanaclocha Luna H (General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain); Burks DJ (The Prince Felipe Research Center-CIPF-, Valencia, Spain; Cervantes A (INCLIVA Health Research Institute, Valencia, Spain); Comas I (Biomedicine Institute of Valencia, Spanish Research Council (CSIC); Díez-Domingo J (Foundation for the promotion of health and biomedical research of the Valencian Community-FISABIO-, Valencia, Spain); Peiro S (Foundation for the promotion of health and biomedical research of the Valencian Community-FISABIO-, Valencia, Spain); González-Candelas F (CIBER in Epidemiology and Public Health, Spain; Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain; Institute for Integrative Systems Biology (I2SysBio), CSIC-University of Valencia, Valencia, Spain); Ferrer Albiach C (Fundación Hospital Provincial de Castelló); Hernández-Aguado I (University Miguel Hernández, Alicante, Spain); Oliver Ramírez N (DataPop Alliance); Sánchez-Payá J (Preventive Medicine Service, Alicante General and University Hospital, Alicante, Spain; Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain; Vento Torres M (Instituto de Investigación Sanitaria La Fe); Zapater Latorre E (Fundación Hospital General Universitario de València); Navarro D (Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain;Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain).
Identifiants
pubmed: 35245583
pii: S0163-4453(22)00124-4
doi: 10.1016/j.jinf.2022.02.035
pmc: PMC8889892
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Letter
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
834-872Informations de copyright
Copyright © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
Références
J Clin Virol. 2021 Apr;137:104784
pubmed: 33711693
J Infect. 2022 Mar;84(3):418-467
pubmed: 34740744
Allergy. 2022 Jan;77(1):271-281
pubmed: 34286856
Clin Microbiol Infect. 2021 Nov;27(11):1672-1677
pubmed: 34174397
J Infect Dis. 2021 Nov 22;224(10):1690-1693
pubmed: 34514509
Clin Microbiol Infect. 2022 Feb;28(2):279-284
pubmed: 34619398
Lancet Reg Health Eur. 2021 Nov;10:100208
pubmed: 34514454
J Infect. 2021 Nov;83(5):559-564
pubmed: 34437927
J Am Geriatr Soc. 2021 Jun;69(6):1441-1447
pubmed: 33768521